Concentrate of Proteolytic Enzymes Enriched in Bromelain

Total Page:16

File Type:pdf, Size:1020Kb

Concentrate of Proteolytic Enzymes Enriched in Bromelain 20 September 2012 EMA/648483/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report NexoBrid Concentrate of proteolytic enzymes enriched in bromelain Procedure No. EMEA/H/C/002246 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier.................................................................................... 5 1.2. Steps taken for the assessment of the product ....................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 9 2.3. Non-clinical aspects .......................................................................................... 20 2.4. Clinical aspects ................................................................................................ 29 2.5. Clinical efficacy ................................................................................................ 36 2.6. Clinical safety .................................................................................................. 89 2.7. Pharmacovigilance...........................................................................................110 2.8. User consultation ............................................................................................118 3. Benefit-Risk Balance............................................................................ 118 4. Recommendations ............................................................................... 122 List of abbreviations aa amino acid BLQ below the Limit of Quantitation BSA Bovine Serum Albumin CDU Casein Digestion Unit CFU Colony Forming Unit c.f. compare (abbr. also: cp. from Latin: confer, “compare”) cm Centimeter CoA Certificates of Analyses CPMP Committee for Proprietary Medicinal Products CPP Critical Process Parameter curr. Ed. Current Edition CV Column Volumes Da Dalton DF Diafiltration DIN Deutsches Institut für Normierung German Industrial Standard DP Drug Product DS Drug Substance EDTA-Na2 Ethylenediaminetetraacetic acid Disodium salt EC European Commission EP European Pharmacopoeia g gram(s) GACP good agricultural and collection practice GMP Good Manufacturing Practice HACCP Hazard analysis and critical control point HAV Hepatitis-A virus HVAC Heating, Ventilating, and Air Conditioning HCl Hydrochloric Acid HMPC Committee on Herbal Medicinal Products HPLC high performance liquid chromatography hrs Hours ICH International Conference on Harmonisation ICP inductively coupled plasma IPA isopropyl alcohol IPC In- Process Controls IR infrared ISO International Organization for Standardization kDa Kilodalton kg Kilogram(s) l litre(s) LAL Limulus Amoebocyte Lysate LFGB Lebensmittel-, Bedarfsgegenstände- und Futtermittelgesetzbuch Law for foodstuffs, consumer goods and feeding stuff (Germany) LOD Limit of Detection LOQ Limit of Quantitation MAA Marketing Authorisation Application mg milligram(s) ml millilitre(s) min minutes mM Millimolar MVD Maximum Valid Dilution Mw Molecular Weight NaCl Sodium chloride NaHSO3 Sodium bisulfite NaOH sodium hydroxide NGD NexoBrid NIR Near- Infrared Analysis nm Nanometer NOAEL No Observed Adverse Effect Level NoV Norovirus OOS Out of Specification OD Optical Density OP Operating Parameter Pa Pascal PAMP pathogen-associated molecular pattern PBS phosphate buffered saline PDE Permitted Daily Exposure Ph. Eur. European Pharmacopoeia pH power of hydrogen (scale measuring acid / alkaline nature of solution) ppm parts per million PTWI Provisional Tolerable Weekly Intake QL Quantitation Limit QP Qualified Person q.s. quantum satis QWP Quality Working Party resp. respectively RH Relative humidity RPM Revolutions per minute RS Reference Standard RSD Relative Standard Deviation RT Room Temperature RT Retention Time SD Standard Deviation SM Starting Material SPC Summary of Product Characteristics TSE Transmissible Spongiform Encephalopathy USP United States Pharmacopoeia UV Ultraviolet V Volt WFI Water for Injection WHO World Health Organisation w/v weight/volume w/w weight/weight 1. Background information on the procedure 1.1. Submission of the dossier The applicant Teva Pharma GmbH submitted on 29 October 2010 an application for Marketing Authorisation to the European Medicines Agency (EMA) for NexoBrid, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 17 December 2009. NexoBrid was designated as an orphan medicinal product EU/3/02/107 on 30 July 2002. NexoBrid was designated as an orphan medicinal product in the following indication: Treatment of partial deep dermal and full thickness burns. The applicant applied for the following indication: Timely, selective removal of eschar in patients with deep partial- and/or full-thickness burns. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies and bibliographic literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/227/2010 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP EMEA-000142-PIP02-09 was not yet completed as some agreed measures were deferred. Information relating to orphan market exclusivity NexoBrid has an Orphan Drug designation. On 30 July 2002 orphan designation (EU/3/02/107) was granted by the European Commission for purified Bromelain for the treatment of partial deep dermal and full thickness burns. Upon request by the MAH a revised opinion was edited in June 2010 (14 June 2010 EMA/COMP/1413/2002 Rev.2). According to the conclusion of this opinion the prevalence of the partial deep dermal and full thickness burns affected approximately 1 in 10,000 people in the European Union (EU). Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. Applicant’s request for consideration New active Substance status The applicant requested the active substance concentrate of proteolitic enzymes enriched in bromelain contained in the above medicinal product to be considered as a new active substance in itself. Protocol Assistance The applicant received Protocol Assistance from the CHMP in NexoBrid on 14 June 2005, 14 May 2008, 18 December 2008 and 19 February 2009. The Protocol Assistance pertained to quality and clinical aspects of the dossier. Licensing status The product was not licensed in any country at the time of submission of the application. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Harald Enzmann Co-Rapporteur: RobertJames Hemmings The application was received by the EMA on 29 October 2010. The procedure started on 17 November 2010. The Rapporteur's first Assessment Report was circulated to all CHMP members on 07 February 2011. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 04 February 2011. During the meeting on 17 March 2011, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 18 March 2011. The applicant submitted the responses to the CHMP consolidated List of Questions on 11 October 2011. The summary report of the inspection carried out at the following sites: MediWound Ltd., 42 Hayarkon St., 81227 Yavne, Israel between 22 and 25 August 2011 and Analyst Research Laboratories, 12 Hamada St, 76703 Rehovot, Israel on 23 August 2011 was issued on 26 September 2011. The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of Questions to all CHMP members on 28 November 2011. During the CHMP meeting on 12-15 December 2011, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant. The applicant submitted the responses to the CHMP List of Outstanding Issues on 10 February 2012. The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of Outstanding Issues to all CHMP members on 9 March 2012. During a meeting of an Ad-hoc Expert group on 7 March 2012, experts were convened to address questions
Recommended publications
  • Enzymes Handling/Processing
    Enzymes Handling/Processing 1 Identification of Petitioned Substance 2 3 This Technical Report addresses enzymes used in used in food processing (handling), which are 4 traditionally derived from various biological sources that include microorganisms (i.e., fungi and 5 bacteria), plants, and animals. Approximately 19 enzyme types are used in organic food processing, from 6 at least 72 different sources (e.g., strains of bacteria) (ETA, 2004). In this Technical Report, information is 7 provided about animal, microbial, and plant-derived enzymes generally, and more detailed information 8 is presented for at least one model enzyme in each group. 9 10 Enzymes Derived from Animal Sources: 11 Commonly used animal-derived enzymes include animal lipase, bovine liver catalase, egg white 12 lysozyme, pancreatin, pepsin, rennet, and trypsin. The model enzyme is rennet. Additional details are 13 also provided for egg white lysozyme. 14 15 Chemical Name: Trade Name: 16 Rennet (animal-derived) Rennet 17 18 Other Names: CAS Number: 19 Bovine rennet 9001-98-3 20 Rennin 25 21 Chymosin 26 Other Codes: 22 Prorennin 27 Enzyme Commission number: 3.4.23.4 23 Rennase 28 24 29 30 31 Chemical Name: CAS Number: 32 Peptidoglycan N-acetylmuramoylhydrolase 9001-63-2 33 34 Other Name: Other Codes: 35 Muramidase Enzyme Commission number: 3.2.1.17 36 37 Trade Name: 38 Egg white lysozyme 39 40 Enzymes Derived from Plant Sources: 41 Commonly used plant-derived enzymes include bromelain, papain, chinitase, plant-derived phytases, and 42 ficin. The model enzyme is bromelain.
    [Show full text]
  • Biochemistry and the Genomic Revolution 1.1
    Dedication About the authors Preface Tools and Techniques Clinical Applications Molecular Evolution Supplements Supporting Biochemistry, Fifth Edition Acknowledgments I. The Molecular Design of Life 1. Prelude: Biochemistry and the Genomic Revolution 1.1. DNA Illustrates the Relation between Form and Function 1.2. Biochemical Unity Underlies Biological Diversity 1.3. Chemical Bonds in Biochemistry 1.4. Biochemistry and Human Biology Appendix: Depicting Molecular Structures 2. Biochemical Evolution 2.1. Key Organic Molecules Are Used by Living Systems 2.2. Evolution Requires Reproduction, Variation, and Selective Pressure 2.3. Energy Transformations Are Necessary to Sustain Living Systems 2.4. Cells Can Respond to Changes in Their Environments Summary Problems Selected Readings 3. Protein Structure and Function 3.1. Proteins Are Built from a Repertoire of 20 Amino Acids 3.2. Primary Structure: Amino Acids Are Linked by Peptide Bonds to Form Polypeptide Chains 3.3. Secondary Structure: Polypeptide Chains Can Fold Into Regular Structures Such as the Alpha Helix, the Beta Sheet, and Turns and Loops 3.4. Tertiary Structure: Water-Soluble Proteins Fold Into Compact Structures with Nonpolar Cores 3.5. Quaternary Structure: Polypeptide Chains Can Assemble Into Multisubunit Structures 3.6. The Amino Acid Sequence of a Protein Determines Its Three-Dimensional Structure Summary Appendix: Acid-Base Concepts Problems Selected Readings 4. Exploring Proteins 4.1. The Purification of Proteins Is an Essential First Step in Understanding Their Function 4.2. Amino Acid Sequences Can Be Determined by Automated Edman Degradation 4.3. Immunology Provides Important Techniques with Which to Investigate Proteins 4.4. Peptides Can Be Synthesized by Automated Solid-Phase Methods 4.5.
    [Show full text]
  • Nexobrid 2 G Powder and Gel for Gel
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT NexoBrid 2 g powder and gel for gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 2 g/22 g gel). The proteolytic enzymes are a mixture of enzymes from the stem of Ananas comosus (pineapple plant). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and gel for gel. The powder is off-white to light tan. The gel is clear and colourless. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. 4.2 Posology and method of administration NexoBrid should only be applied by trained healthcare professionals in specialist burn centres. Posology 2 g NexoBrid powder in 20 g gel is applied to a burn wound area of 100 cm2. NexoBrid should not be applied to more than 15% Total Body Surface Area (TBSA) (see also section 4.4, Coagulopathy). NexoBrid should be left in contact with the burn for a duration of 4 hours. There is very limited information on the use of NexoBrid on areas where eschar remained after the first application.
    [Show full text]
  • Molecular Insights Into Bromelain Application in Industry and Health Care
    Biosc.Biotech.Res.Comm. Special Issue Vol 13 No 15 (2020) Pp-36-46 Molecular Insights into Bromelain Application in Industry and Health Care Sushma S. Murthy and T. Bala Narsaiah 1Research Scholar, Department of Chemical Engineering, JNTUA College of Engineering, Ananthapuram-515002, Andhra Pradesh, India 2Department of Chemical Engineering, JNTUA College of Engineering, Ananthapuram-515002, Andhra Pradesh, India ABSTRACT Bromelain is a cysteine protease derived from the stem and fruit of the pineapple. It has a significant role in pharmacological and clinical applications. Studies have shown Bromelain to be a potent photoactive compound that has a wide application in industry. It has also been shown to be effective in treatment of cancer, inflammation, and allergies. It has a distinct immunomodulatory activity which forms an important strategy in its utilization as a therapeutic agent. Bromelain plays a significant role at molecular level by regulating the expression of proteins that are potential therapeutic targets. Bromelain is used extensively worldwide as an herbal medicine as it promises good efficacy and has no side effects. This paper reviews the general characteristics of Bromelain, its separation process, and its use in industries and healthcare as a therapeutic agent. The present review identifies that there is lack of knowledge pertaining to the mode of action of Bromelain in inhibiting transcriptional factors and in controlling cancer. An in-detail analysis in this area might help in expanding the therapeutic scope of Bromelain. KEY WORDS: BROMELAIN, CANCER, PHARMacOLOGICAL actiVITY, SEpaRatiON, TRANSCRIPTION FactORS. INTRODUCTION because of its wide benefits to the human system. The stem part of the plant, which is inexpensive and is usually The Bromelain protease is isolated from the stem and discarded, has a high concentration of bromelain and fruit of Pineapple (Ananas comosus,).
    [Show full text]
  • Development of Granulation Tissue Mimetic Scaffolds for Skin Healing
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 10-4-2018 12:30 PM Development Of Granulation Tissue Mimetic Scaffolds For Skin Healing Adam Hopfgartner The University of Western Ontario Supervisor Hamilton, Douglas W. The University of Western Ontario Co-Supervisor Pickering, J. Geoffrey. The University of Western Ontario Graduate Program in Biomedical Engineering A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Engineering Science © Adam Hopfgartner 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Biomaterials Commons, and the Molecular, Cellular, and Tissue Engineering Commons Recommended Citation Hopfgartner, Adam, "Development Of Granulation Tissue Mimetic Scaffolds For Skin Healing" (2018). Electronic Thesis and Dissertation Repository. 5767. https://ir.lib.uwo.ca/etd/5767 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Impaired skin healing is a significant and growing clinical concern, particularly in relation to diabetes, venous insufficiency and immobility. Previously, we developed electrospun scaffolds for the delivery of periostin (POSTN) and connective tissue growth factor 2 (CCN2), matricellular proteins involved in the proliferative phase of healing. This study aimed to design and validate a novel electrosprayed coaxial microsphere for the encapsulation of fibroblast growth factor 9 (FGF9), as a component of the POSTN/CCN2 scaffold, to promote angiogenic stability during wound healing. For the first time, we observed a pro-proliferative effect of FGF9 on human dermal fibroblasts (HDF) in vitro, indicating a potential cellular mechanism of action during wound healing.
    [Show full text]
  • International Journal of Advanced and Applied Sciences, 4(12) 2017, Pages: 31-35
    International Journal of Advanced and Applied Sciences, 4(12) 2017, Pages: 31-35 Contents lists available at Science-Gate International Journal of Advanced and Applied Sciences Journal homepage: http://www.science-gate.com/IJAAS.html Tertiary structure prediction of bromelain from Ananas Comosus using comparative modelling method Fatahiya Mohamed Tap 1, Fadzilah Adibah Abd Majid 2, *, Nurul Bahiyah Ahmad Khairudin 1 1Chemical Energy Conversion and Applications Group, Malaysia Japan International Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, Malaysia 2Institute of Marine Biotechnology, Universiti Malaysia Terengganu, 21030 Kuala Terengganu, Malaysia ARTICLE INFO ABSTRACT Article history: Bromelain is a general name for a family of sulfhydryl which can be found in Received 21 February 2017 the proteolytic enzyme group from pineapples (Ananas Comosus). This study Received in revised form focuses on the prediction of three dimensional structures (3D) of stem 2 October 2017 bromelain using the method of comparative modelling. The amino acid Accepted 8 October 2017 sequence of bromelain was obtained from the NCBI database was used as a tool to search for proteins with known 3D structures related to the target Keywords: sequence. Suitable template was chosen based on >30% sequence similarity Bromelain and lowest e-value. Based on these criteria, 1YAL was selected as the best Comparative modelling template with 55% of sequence similarity and 9x10-52 of e-value. Sequence alignment © 2017 The Authors. Published by IASE. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction industrial and pharmacology area, therefore it is essential to maintain and improve bromelain *Bromelain can be derived from stem and fruit of properties in conformation and catalytic activity in pineapples.
    [Show full text]
  • The Wound/Burn Guidelines –
    doi: 10.1111/1346-8138.13288 Journal of Dermatology 2016; : 1–22 GUIDELINE The wound/burn guidelines – 6: Guidelines for the management of burns Yuichiro YOSHINO,1 Mikio OHTSUKA,2 Masakazu KAWAGUCHI,3 Keisuke SAKAI,4 Akira HASHIMOTO,5 Masahiro HAYASHI,3 Naoki MADOKORO,6 Yoshihide ASANO,7 Masatoshi ABE,8 Takayuki ISHII,9 Taiki ISEI,10 Takaaki ITO,11 Yuji INOUE,12 Shinichi IMAFUKU,13 Ryokichi IRISAWA,14 Masaki OHTSUKA,15 Fumihide OGAWA,16 Takafumi KADONO,7 Tamihiro KAWAKAMI,17 Ryuichi KUKINO,18 Takeshi KONO,19 Masanari KODERA,20 Masakazu TAKAHARA,21 Miki TANIOKA,22 Takeshi NAKANISHI,23 Yasuhiro NAKAMURA,24 Minoru HASEGAWA,9 Manabu FUJIMOTO,9 Hiroshi FUJIWARA,25 Takeo MAEKAWA,26 Koma MATSUO,27 Osamu YAMASAKI,15 Andres LE PAVOUX,28 Takao TACHIBANA,29 Hironobu IHN,12 The Wound/Burn Guidelines Committee 1Department of Dermatology, Japanese Red Cross Kumamoto Hospital, Kumamoto, 2Department of Dermatology, Fukushima Medical University, Fukushima, 3Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, 4Intensive Care Unit, Kumamoto University Hospital, Kumamoto, 5Department of Dermatology, Tohoku University Graduate School of Medicine, Miyagi, 6Department of Dermatology, Mazda Hospital, Hiroshima, 7Department of Dermatology, Faculty of Medicine,University of Tokyo, Tokyo, 8Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, 9Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 10Department of Dermatology, Kansai
    [Show full text]
  • Role of Systemic Enzymes in Infections
    Article ID: WMC002495 2046-1690 Role of Systemic Enzymes in Infections Corresponding Author: Dr. Sukhbir Shahid, Consultant Pediatrician, Pediatrics - India Submitting Author: Dr. Sukhbir Shahid, Consultant Pediatrician, Pediatrics - India Article ID: WMC002495 Article Type: Review articles Submitted on:22-Nov-2011, 08:16:56 AM GMT Published on: 22-Nov-2011, 02:34:00 PM GMT Article URL: http://www.webmedcentral.com/article_view/2495 Subject Categories:COMPLEMENTARY MEDICINE Keywords:Enzymes, Systemic enzymes, Infections, Sepsis, Proteolytic, Supplementary How to cite the article:Shahid S . Role of Systemic Enzymes in Infections . WebmedCentral COMPLEMENTARY MEDICINE 2011;2(11):WMC002495 Source(s) of Funding: None Competing Interests: None WebmedCentral > Review articles Page 1 of 13 WMC002495 Downloaded from http://www.webmedcentral.com on 23-Dec-2011, 07:57:46 AM Role of Systemic Enzymes in Infections Author(s): Shahid S Abstract infections[4]. The ‘battle’ between the host’s immunity and organism leads to a lot of ‘molecular’morbidity and mortality. Anti-infective agents do help but at times benefit is marginal. These agents may sometimes Enzymes are complex macromolecules of amino-acids worsen the situation through release of immune which bio-catalyse various body processes. Adequate complexes and dead bacilli into the blood stream. concentrations of enzymes are essential for optimal They also fail to reverse the hemodynamic instability functioning of the immune system. During infections, and immune paralysis characteristic of these body’s enzymatic system is attacked and hence the infections[4]. Supplementation with drugs targeted immune system is also likely to derange. This may be against this ‘choatic’ or ‘dysfunctional’ immune detrimental for the host’s well-being and existence.
    [Show full text]
  • Food and Drugs
    21 Parts 300 to 499 Revised as of April 1, 2004 Food and Drugs Containing a codification of documents of general applicability and future effect As of April 1, 2004 With Ancillaries Published by Office of the Federal Register National Archives and Records Administration A Special Edition of the Federal Register VerDate mar<24>2004 15:46 Apr 22, 2004 Jkt 203068 PO 00000 Frm 00001 Fmt 8091 Sfmt 8091 Y:\SGML\203068F.XXX 203068F U.S. GOVERNMENT PRINTING OFFICE WASHINGTON : 2004 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800; DC area (202) 512-1800 Fax: (202) 512-2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate mar<24>2004 15:46 Apr 22, 2004 Jkt 203068 PO 00000 Frm 00002 Fmt 8092 Sfmt 8092 Y:\SGML\203068F.XXX 203068F Table of Contents Page Explanation ................................................................................................ v Title 21: Chapter I—Food and Drug Administration, Department of Health and Human Services (Continued) ................................................. 3 Finding Aids: Material Approved for Incorporation by Reference ............................ 335 Table of CFR Titles and Chapters ....................................................... 337 Alphabetical List of Agencies Appearing in the CFR ......................... 355 List of CFR Sections Affected ............................................................. 365 iii VerDate May<04>2004 11:24 May 20, 2004 Jkt 203068 PO 00000 Frm 00003 Fmt 8092 Sfmt 8092 Y:\SGML\203068F.XXX 203068F Cite this Code: CFR To cite the regulations in this volume use title, part and section num- ber. Thus, 21 CFR 300.50 refers to title 21, part 300, section 50. iv VerDate mar<24>2004 15:46 Apr 22, 2004 Jkt 203068 PO 00000 Frm 00004 Fmt 8092 Sfmt 8092 Y:\SGML\203068F.XXX 203068F Explanation The Code of Federal Regulations is a codification of the general and permanent rules published in the Federal Register by the Executive departments and agen- cies of the Federal Government.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Chapter 11 Cysteine Proteases
    CHAPTER 11 CYSTEINE PROTEASES ZBIGNIEW GRZONKA, FRANCISZEK KASPRZYKOWSKI AND WIESŁAW WICZK∗ Faculty of Chemistry, University of Gdansk,´ Poland ∗[email protected] 1. INTRODUCTION Cysteine proteases (CPs) are present in all living organisms. More than twenty families of cysteine proteases have been described (Barrett, 1994) many of which (e.g. papain, bromelain, ficain , animal cathepsins) are of industrial impor- tance. Recently, cysteine proteases, in particular lysosomal cathepsins, have attracted the interest of the pharmaceutical industry (Leung-Toung et al., 2002). Cathepsins are promising drug targets for many diseases such as osteoporosis, rheumatoid arthritis, arteriosclerosis, cancer, and inflammatory and autoimmune diseases. Caspases, another group of CPs, are important elements of the apoptotic machinery that regulates programmed cell death (Denault and Salvesen, 2002). Comprehensive information on CPs can be found in many excellent books and reviews (Barrett et al., 1998; Bordusa, 2002; Drauz and Waldmann, 2002; Lecaille et al., 2002; McGrath, 1999; Otto and Schirmeister, 1997). 2. STRUCTURE AND FUNCTION 2.1. Classification and Evolution Cysteine proteases (EC.3.4.22) are proteins of molecular mass about 21-30 kDa. They catalyse the hydrolysis of peptide, amide, ester, thiol ester and thiono ester bonds. The CP family can be subdivided into exopeptidases (e.g. cathepsin X, carboxypeptidase B) and endopeptidases (papain, bromelain, ficain, cathepsins). Exopeptidases cleave the peptide bond proximal to the amino or carboxy termini of the substrate, whereas endopeptidases cleave peptide bonds distant from the N- or C-termini. Cysteine proteases are divided into five clans: CA (papain-like enzymes), 181 J. Polaina and A.P. MacCabe (eds.), Industrial Enzymes, 181–195.
    [Show full text]
  • ^ P X R, for the PURPOSES of INFORMATION ONLY
    WORLD INTELLECTUAL PROPERTY ORGANIZATION PCT International Bureau INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 6 : (11) International Publication Number: WO 98/49190 C07K 5/06, 5/08, 5/10 A l (43) International Publication Date: 5 November 1998 (05.11.98) (21) International Application Number: PCT/US98/08259 (74) Agents: BURKE, John, E. et al.; Cushman Darby & Cushman, Intellectual Property Group of Pillsbury Madison & Sutro, (22) International Filing Date: 24 April 1998 (24.04.98) 1100 New York Avenue, N.W., Washington, DC 20005 (US). (30) Priority Data: 60/044,819 25 April 1997 (25.04.97) US (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, Not furnished 23 April 1998 (23.04.98) US BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, (71) Applicant (for all designated States except US): CORTECH, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, INC. [US/US]; 6850 North Broadway, Denver, CO 80221 TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO (US). patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (72) Inventors; and patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, (75) Inventors/Applicants(for US only): SPRUCE, Lyle, W. IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, [US/US]; 948 Camino Del Sol, Chula Vista, CA 91910 CG, Cl, CM, GA, GN, ML, MR, NE, SN, TD, TG).
    [Show full text]